FIELD: medicine.
SUBSTANCE: invention refers to medicine and pharmacology. A method of treating of at least one vascular disease in a patient involving a stage of introduction into the patient suffering at least one vascular disease or manifesting its biomarkers of a therapeutically effective amount of a central dopamine agonist with said central dopamine agonist is effective for treating said at least one vascular disease in said patient; wherein said dopamine agonist is introduced so that the peak plasma concentration of the dopamine agonist is reached between 04:00 and 12:00 o'clock, while blood bioavailability of said dopamine agonist is reduced within approximately 50% of the peak plasma concentration approximately 2 to 6 hours after termination of a day peak or the steady-state plasma concentration of the dopamine agonist. According to one version of implementation, the central dopamine agonist represents bromocriptine optionally combined with a pharmaceutically acceptable carrier.
EFFECT: invention provides higher clinical effectiveness.
9 cl, 10 ex, 12 dwg
